Canaccord Genuity Downgrades Pacira Pharmaceuticals (PCRX) to Hold

Canaccord Genuity downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold with a price target of $33.00 (from $44.00).

Analyst Dewey Steadman says the IMS continues to disappoint and therefore steps to the sidelines noting he expects share price pressures following guidance and efforts by management to regain investor confidence in 2018.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $33.20 Friday.

You May Also Be Interested In

• Oracle (ORCL) PT Raised to $250 at UBS Following Q1 Results
• Jazz Pharmaceuticals (JAZZ) PT Raised to $337 at UBS on GEA Approval for Ziihera
• HubSpot Inc (HUBS) PT Raised to $225 at Stifel Ahead of UNBOUND Conference